191360 Issues and Obstacles in the Identification and Communication of Adverse Drug Effects

Monday, October 27, 2008: 11:10 AM

Beatrice Golomb, MD, PhD , University of California San Diego, School of Medicine, La Jolla, CA
Selection practices and other considerations have been recognized to promote identification of drug benefits relative to harms in clinical trials. Indeed, identification and dissemination of drug benefits relative to harms is promoted by a spectrum of factors ranging from selective publication practices to ghostwritten review articles. Evidence for propagation of these disparities at many levels will be presented; and potential approaches to remediate this imbalance will be suggested.

Learning Objectives:
1. Define the considerations that have been recognized to promote the identification of drug benefits relative to harms in clinical trials. 2. Describe the evidence for the propagation of disparities in reporting drug harms versus benefits.

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: tba
Any relevant financial relationships? No

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.

See more of: Drug Safety and FDA Reform: Are we better off now?
See more of: Medical Care